<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 580 poor mobilizers with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received plerixafor plus granulocyte CSF with or without chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Overall, the collection yield was significantly higher in MM patients (&gt;2.0 × 10(6) CD34+ cells/kg: 81.6%; &gt;5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (&gt;2.0 × 10(6) CD34+ cells/kg: 64.8%; &gt;5.0 × 10(6) CD34+ cells/kg: 12.6%; P&lt;0.0001) and also significantly higher in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> patients (&gt;2.0 × 10(6) CD34+ cells/kg: 81.5%; &gt;5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013) </plain></SENT>
<SENT sid="4" pm="."><plain>In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required </plain></SENT>
</text></document>